IRLAB announced yesterday that Richard Godfrey has been appointed new CEO of IRLAB, succeeding Nicholas Waters. Godfrey will focus on IRLAB’s commercial development and interactions with the capital markets. He has international experience in leadership positions within the life science industry, including CEO of BerGenBio for 12 years. He will step in into his new role as CEO on 1 July.
Nicholas Waters will focus on R&D and clinical development
Nicholas Waters, current CEO and co-founder of IRLAB, has been appointed new Executive Vice President and Head of R&D, where his main role will be related to advancing the current and upcoming clinical programmes and to further leverage IRLAB’s ISP research platform.
New roles to allow narrower focus
The company expects the switch up will allow Waters to better focus on the R&D segment (where his main area of expertise lies) and leverage the ISP platform to add new drug candidates to IRLAB’s pipeline as well as moving forward the current clinical development, while the international commercial experience of Godfrey should be positive for the company in future commercial interactions. We expect a neutral share price reaction to the news.
Läs mer på ABG Sundal Collier
Aktuellt
SENASTE
